Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 38 of 1,261
  1. US 12324843

    Compositions and methods for delivery of biomacromolecule agents

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  2. US 12325752

    Immunoglobulin proteins that bind to NPR1 agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  3. WO 2025114603

    COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Jun 5, 2025 · Expires May 31, 2045

    granted
  4. WO 2025114430

    COMPOSITION À LIBÉRATION MODIFIÉE

    ABBOTT LABORATORIES GMBH [DE] · Granted Jun 5, 2025 · Expires May 31, 2045

    granted
  5. WO 2025114529

    ANTICORPS MULTISPÉCIFIQUES RECONNAISSANT L'ALBUMINE SÉRIQUE HUMAINE, TCR ET FRACTION RECONNAISSANT L'ANTIGÈNE TUMORAL

    ABLYNX NV [BE] · Granted Jun 5, 2025 · Expires May 31, 2045

    granted
  6. EP 4563165

    PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE

    ABBVIE INC [US] · Granted Jun 4, 2025 · Expires May 30, 2045

    granted
  7. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Karyopharm Therapeutics Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  8. US 12318376

    Compositions of a polyorthoester and an aprotic solvent

    Heron Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  9. US 12318375

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  10. US 12318397

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  11. US 12318362

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  12. US 12318418

    Modified adenoviruses

    University College Cardiff Consultants Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  13. US 12318401

    Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

    The Regents of the University of California · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  14. US 12318426

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  15. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  16. US 12319703

    Macrocyclic fused pyrazoles as Mcl-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  17. US 12318454

    Bicyclic peptide ligands specific for MT1-MMP

    BicycleRD Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  18. US 12318457

    Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  19. US 12319724

    IL2 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  20. US 12318427

    Methods and compositions for modulation of tau proteins

    Sangamo Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  21. US 12318364

    Isoflavonoid compositions and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  22. US 12318483

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  23. US 12319684

    Agonists of the apelin receptor and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  24. US 12319708

    Agonists of peroxisome proliferator-activated receptor alpha (PPARα) and methods of use

    The Board of Regents of the University of Oklahoma · Granted Jun 3, 2025 · Expires May 29, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.